NEW
YORK, Oct. 17, 2024 /PRNewswire/ -- Report with
the AI impact on market trends - The Global Acute Ischemic Stroke
Therapeutics Market size is estimated to grow by USD 1.74 billion from 2024-2028, according to
Technavio. The market is estimated to grow at a CAGR of
6.1% during the forecast period.Rising prevalence of
cardiovascular diseases is driving market growth, with a
trend towards integrating genomic and clinical data through
translational bioinformatics in acute ischemic stroke management.
However, unmet needs for anticoagulant reversal agents
poses a challenge - Key market players include Amgen Inc.,
AstraZeneca Plc, Athersys Inc., Bayer AG, Biogen Inc., Boehringer
Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi
Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson
Services Inc., Medtronic PLC, Merck and Co. Inc., NoNO Inc., Pfizer
Inc., SanBio Co. Ltd., Sanofi SA, Stryker Corp., and Teva
Pharmaceutical Industries Ltd..
Key insights into market evolution with
AI-powered analysis. Explore trends, segmentation, and growth
drivers- View the snapshot of this report
Acute Ischemic
Stroke Therapeutics Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
6.1%
|
Market growth
2024-2028
|
USD 1742
million
|
Market
structure
|
Fragmented
|
YoY growth 2022-2023
(%)
|
5.7
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
39%
|
Key
countries
|
US, UK, Germany, China,
and Canada
|
Key companies
profiled
|
Amgen Inc., AstraZeneca
Plc, Athersys Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim
International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co.
Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson Services Inc.,
Medtronic PLC, Merck and Co. Inc., NoNO Inc., Pfizer Inc., SanBio
Co. Ltd., Sanofi SA, Stryker Corp., and Teva Pharmaceutical
Industries Ltd.
|
Market Driver
Acute Ischemic Stroke (AIS) is a complex cardiac disorder
requiring integration of genotypic and clinical data for effective
treatment and prevention. Modern approaches, such as Translational
Bioinformatics (TBI), are being developed to analyze heterogeneous
features from bioinformatics, biostatistics, statistical genetics,
and clinical informatics. TBI acts as a data-storage source,
integrating and improving data representation using tools like
Ontologies and Controlled Vocabulary (CV). In AIS, genotypic data
(presence or absence of risk genes like HDAC9, PITX2, ZFHX3, NINJ2,
PRKCH, and 9p21) and clinical data (clinical tests like magnetic
resonance imaging and patient history) are integrated. The clinical
history includes age of diagnosis and family history of sudden
death. Compilation of these details enhances doctors' understanding
of each patient's clinical scenario, leading to improved treatment
approaches. This integration of genotypic and clinical data will
fuel the growth of the AIS therapeutics market during the forecast
period.
The Acute Ischemic Stroke (AIS) market is witnessing significant
growth due to the increasing prevalence of AIS caused by
atherosclerosis plaques obstructing blood flow to the brain.
Neuroimaging techniques such as Computed Tomography (CT) scans and
Magnetic Resonance Imaging (MRI) scans play a crucial role in
diagnosing AIS. Surgical equipment like Carotid Endarterectomy and
Angioplasty are used for removing blockages in arteries, while
Endovascular Mechanical Thrombectomy and clot dissolving drugs like
Tissue Plasminogen Activator (tPA) and tenecteplase are used for
removing blood clots. The market is driven by an aging population,
rising prevalence of conditions like high blood pressure, diabetes,
and obesity, and advancements in neuroimaging technologies. Key
players in the market include Defense Health Agency, alteplase
(Drug Class: Thrombolytics), tenecteplase (Drug Class:
Thrombolytics), antiplatelets, anticoagulants, statins,
antihypertensives, and other drug classes. The route of
administration for these drugs can be intravenous or
intracranial.
Request Sample of our comprehensive
report now to stay ahead in the AI-driven market evolution!
Market Challenges
- The Acute Ischemic Stroke Therapeutics Market faces a
significant challenge due to the limited availability of antidotes
for anticoagulant reversal agents. While anticoagulants are
essential for treating Acute Ischemic Strokes (AIS), they carry the
risk of excessive bleeding, which can be reversed using reversal
agents. Currently, vitamin K, protamine, and prothrombin complex
concentrates are available to reverse the effects of warfarin and
heparin. However, the acceptance of these drugs is low due to the
scarcity of antidotes for newer anticoagulants like direct thrombin
inhibitors and factor XA inhibitors. The recent approval of
idarucizumab, an antidote for dabigatran, is a positive
development. However, ongoing research is necessary to develop
reversal agents for newer anticoagulants, which will expand the
market's growth potential during the forecast period. The unmet
need for anticoagulant reversal agents hinders the adoption of
novel anticoagulants, negatively impacting the market's
growth.
- The Acute Ischemic Stroke Therapeutics market is focused on
developing innovative treatments for blood clots in the arteries
supplying the brain. The primary challenges include the complexity
of the brain's blood vessels and the need for rapid intervention to
prevent brain cell damage. Surgical equipment like mechanical
thrombectomy devices and clot dissolving drugs such as alteplase
and tenecteplase are key solutions. An aging population, medical
conditions like high blood pressure, diabetes, and obesity, and
neuroimaging technologies like CT scans and MRI scans are
significant market drivers. Defense Health Agency and other
healthcare providers utilize various drug classes, including
thrombolytics, antiplatelets, anticoagulants, statins,
antihypertensives, and others. The distribution channel includes
hospital pharmacies, retail pharmacies, and online pharmacies, with
the route of administration being parenteral.
Discover how AI is revolutionizing market
trends- Get your access now!
Segment Overview
This acute ischemic stroke therapeutics market report
extensively covers market segmentation by
- Type
- 1.1 Thrombolytics
- 1.2 Anticoagulants
- 1.3 Antiplatelets
- 1.4 Antihypertensives
- 1.5 Others
- Distribution Channel
- 2.1 Hospital pharmacies
- 2.2 Retail pharmacies
- 2.3 Online pharmacies
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Thrombolytics- Thrombolytic agents, also
known as clot-busting drugs, are the primary therapeutics used for
treating Acute Ischemic Strokes (AIS). The process of breaking down
blood clots, known as thrombolysis, is essential for restoring
blood flow to the affected brain areas. The most widely used
thrombolytic agent for AIS is Activase, a tissue plasminogen
activator sold under the brand name by Roche. The FDA recommends a
dosage of 0.9 mg per kg body weight infused intravenously over an
hour, with 10% administered as an initial bolus within one minute.
Activase is approved for various indications, including AIS, acute
myocardial infarction (AMI), and acute massive pulmonary embolism
(PE). The high market share of thrombolytics can be attributed to
the availability of approved AIS therapeutics like Activase, which
has been on the market since 1987. This drug's widespread use is
due to its ability to produce improved neurological outcomes in a
significant number of AIS patients, leading to a high adoption rate
among both physicians and patients. The inclusion criteria for
administering IV treatment with Activase include a diagnosis of AIS
causing neurological damage, minor neurological symptoms, onset of
symptoms within 4.5 hours, no history of head trauma or prior AIS,
no evidence of active bleeding, and normal blood pressure, among
others. These factors contribute to the continued growth of the
thrombolytics segment in the market during the forecast period.
Download a Sample of our
comprehensive report today to discover how AI-driven innovations
are reshaping competitive dynamics
Research Analysis
Acute Ischemic Stroke (AIS) is a medical condition characterized
by the sudden interruption of blood supply to a part of the brain,
leading to brain cell damage. Diagnostic tools for AIS include
Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Carotid
Ultrasound, Cerebral Angiography, Electrocardiography,
Echocardiography, and various imaging techniques. Treatment options
include Carotid Endarterectomy, Angioplasty, Endovascular
Mechanical Thrombectomy, Thrombolytics such as alteplase and
tenecteplase, Anticoagulants, Antiplatelets, Antihypertensives,
Statins, and other Drug Classes. The route of administration for
these therapeutics can be oral or parenteral. The distribution
channel for these therapeutics includes Hospital pharmacies and
Retail pharmacies. AIS is often caused by atherosclerosis plaques
obstructing blood vessels.
Market Research Overview
Acute Ischemic Stroke (AIS) is a medical condition caused by a
sudden disruption of blood flow to the brain due to the formation
of blood clots in the arteries supplying the brain. AIS is a
leading cause of long-term disability and the fifth leading cause
of death worldwide. Neuroimaging techniques such as Computed
Tomography (CT) and Magnetic Resonance Imaging (MRI) are essential
in diagnosing AIS. Surgical interventions like Carotid
Endarterectomy, Angioplasty, and Endovascular Mechanical
Thrombectomy are used to remove the clots and restore blood flow.
Medications like Tissue Plasminogen Activator (tPA),
Anticoagulants, Antiplatelets, Antihypertensives, and Statins are
used to treat AIS. Risk factors for AIS include atherosclerosis
plaques, aging population, high blood pressure, diabetes, and
obesity. The market for acute ischemic stroke therapeutics includes
various drug classes such as Thrombolytics, Antiplatelets,
Anticoagulants, and other Drug Classes. The route of administration
for these drugs can be oral or parenteral, and they are distributed
through hospital pharmacies, retail pharmacies, and online
pharmacies. Neuroimaging technologies, including CT scans and MRI
scans, play a crucial role in diagnosing AIS and monitoring its
progression. The Defense Health Agency is one of the significant
consumers of these therapeutics due to the high prevalence of
stroke among military personnel. Some common diagnostic tools
include Electrocardiography, Echocardiography, and Cerebral
Angiography. The market for acute ischemic stroke therapeutics is
expected to grow significantly due to the increasing aging
population, rising prevalence of risk factors, and advancements in
neuroimaging technologies and therapeutic interventions.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Type
-
- Thrombolytics
- Anticoagulants
- Antiplatelets
- Antihypertensives
- Others
- Distribution Channel
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acute-ischemic-stroke-therapeutics-market-to-grow-by-usd-1-74-billion-from-2024-2028--driven-by-rising-cardiovascular-disease-prevalence-and-ai-driven-market-transformation---technavio-302278833.html
SOURCE Technavio